/Companies

Neuvivo, Inc.

Palo Alto, US · 1 known investors

Find your way into Neuvivo, Inc.

Sign up to see every warm intro you have to Neuvivo, Inc.

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Neuvivo, Inc. team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Neuvivo is a biopharmaceutical company developing therapies for ALS and other motor neuron diseases, with a lead candidate (NP001) that targets neuroinflammation at the neuromuscular junction. It focuses on neuroimmunologic, science-based approaches to treat neurodegenerative diseases for patient communities.

Founders & leadership

MM
Michael McGrathNamed on SEC filing
VV
Virit VichitvadakanNamed on SEC filing
PP
Pornsit PoovanakijjakornNamed on SEC filing
RB
Robert BaffiNamed on SEC filing
JC
John CurnutteNamed on SEC filing

Investors · 1

Reported raises · per SEC filings

Form D private placements

$1.4M disclosed across 1 round · 2026

▶$1.4MraisedNov 2026 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael McGrathExecutive Officer, Director
  • Virit VichitvadakanDirector
  • Pornsit PoovanakijjakornDirector
  • Robert BaffiDirector
  • John CurnutteDirector
Offering amount
$9.5M
Amount sold
$1.4M
Proceeds to insiders
$416K
First sale
Oct 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Neuvivo, Inc. do?
Neuvivo is a biopharmaceutical company developing therapies for ALS and other motor neuron diseases, with a lead candidate (NP001) that targets neuroinflammation at the neuromuscular junction. It focuses on neuroimmunologic, science-based approaches to treat neurodegenerative diseases for patient communities.
Who are Neuvivo, Inc.'s investors?
Neuvivo, Inc.'s investors include Samsara BioCapital.
How much funding has Neuvivo, Inc. raised?
Neuvivo, Inc. has disclosed $1.4M raised across 1 round.
Where is Neuvivo, Inc. headquartered?
Neuvivo, Inc. is headquartered in Palo Alto, US.